Overview

Chlamydia trachomatis is one of the most prevalent sexually transmitted infections (STIs) worldwide, with approximately 129 million new cases annually,¹ posing a significant public health threat. This gram-negative bacterium often goes undetected due to its asymptomatic nature, leading to serious health complications such as infertility, chronic pain, and gynecologic cancers. The infection not only affects individual health but also imposes substantial economic burdens due to the costs of screening and treatment programs.¹ Furthermore, the rise of antibiotic resistance complicates treatment efforts, making it even more crucial to manage this infection effectively.² Through regular screenings, public education, and ensuring accessible and appropriate treatment, we can mitigate these impacts and improve global health outcomes.

Symptoms of chlamydia

Chlamydia trachomatis can cause many infections in the genital and urinary systems and even affect other parts of the body. Although, usually most patients are asymptomatic, below are some of the frequent symptoms associated with the infection:

• Cervicitis: Vaginal discharge, bleeding, belly pain, or pain when peeing
• Pelvic Inflammatory Disease (PID): Causes belly or pelvic pain, nausea, fever, back pain, pain during sex, and sometimes bleeding after sex
• Urethritis: Can lead to frequent urination, pain when peeing, and discharge from the urethra (the tube where pee comes out)
• Perihepatitis (Fitz-Hugh-Curtis Syndrome): Causes belly pain, especially on the right side, and is often linked with PID
• Epididymitis: Brings pain and swelling in one testicle, possibly with fever
• Prostatitis: Can cause pain when peeing, trouble peeing, pelvic pain, and pain during ejaculation
• Reactive Arthritis: Rarely happens, but it can cause joint pain, pain when peeing, and eye inflammation
• Proctitis: Causes pain, discharge, and bleeding from the rectum, mainly in those who have anal sex
• Conjunctivitis: An eye infection causing redness and irritation, often from contact with infected genital secretions
• Pharyngitis: A sore throat, sometimes caused by chlamydia, detected through medical tests
• Lymphogranuloma Venereum: Leads to painless genital sores and swollen lymph nodes
• Pneumonia (in infants): Causes coughing, congestion, and sometimes fever in babies, usually appearing a few weeks after birth³

Diagnosing chlamydia

Diagnosing chlamydia often requires opportunistic screening, which involves testing individuals without symptoms during routine healthcare visits. In Canada, the Task Force on Preventive Health Care recommends annual opportunistic screening for chlamydia for all sexually active individuals under 30 years old. This proactive approach not only aids in early detection but also helps destigmatize discussions about sexual health, fostering open dialogue between patients and healthcare providers.⁴

For individuals at higher risk of contracting chlamydia, such as those with multiple sexual partners or individuals assigned male at birth (AMAB) who engage in sexual activity with other AMAB individuals, more frequent screening is advised. Current guidelines suggest annual anatomic site-based screening for chlamydia for AMAB individuals, with more frequent screening (every 3-6 months) for at-risk individuals, including those taking human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) or living with HIV. Additionally, pregnant individuals should undergo chlamydia screening at their first prenatal visit, with further testing in the third trimester if initial results are positive or if ongoing risk factors are present.⁴

Clinicians play a pivotal role in determining the appropriate screening approach based on information gathered from the patient's sexual history. Even in the absence of symptoms or known sexual exposures, consideration should be given to screening extragenital sites such as the rectum (which connects the large intestine to the anal canal) and oropharynx (middle of the throat).⁴ This comprehensive screening strategy is essential as relying solely on symptoms or testing only sites with known exposure may result in missed diagnoses. By implementing effective screening protocols, healthcare providers can improve the timely detection and management of chlamydia infections, ultimately contributing to better public health outcomes.

Treatment guidelines for chlamydia

Treating chlamydia typically involves antibiotics such as azithromycin or doxycycline. Azithromycin is favoured for its single-dose convenience, while doxycycline requires a week-long course of twice-daily doses. Sometimes, other antibiotics like erythromycin or levofloxacin are used if azithromycin or doxycycline isn't suitable or available. However, these alternatives might not be as effective and can cause side effects like stomach upset. These antibiotics work by halting the bacteria's growth and spread in the body. Although recent research comparing the two in over 2700 people, predominantly AMAB, findings suggest that doxycycline may be more effective in AMAB individuals, particularly in preventing microbiological failure. Despite these results, the decision on which antibiotic to use should be guided by healthcare providers based on individual circumstances and considerations.⁵

Ensuring proper antibiotic adherence is critical in chlamydia treatment. It's imperative to follow the prescribed dosage and complete the full course, even if symptoms improve or disappear. This helps eradicate all bacteria and reduces the risk of reinfection or antibiotic resistance. Additionally, after completing treatment, retesting is essential to confirm the infection has cleared entirely, especially if there was unprotected sex during treatment or if the partner wasn't treated. Prompt testing and treatment are crucial as untreated chlamydia can lead to severe complications like infertility or pelvic inflammatory disease.

While the research primarily focused on AMAB individuals, the inclusion of more assigned female at birth (AFAB) individuals in future studies is essential to enhance treatment options, particularly in low-income settings. Understanding how antibiotics affect AFAB individuals with chlamydia and identifying the most effective treatment regimens are vital steps in improving global chlamydia management.⁵ Furthermore, ongoing research should delve into factors like treatment adherence, antibiotic resistance, and risk of reinfection to optimize chlamydia treatment strategies and reduce its impact on public health.

The rise of antibiotic resistance in chlamydia treatment 

Antibiotic resistance is a pressing concern in the treatment of bacterial infections, including chlamydia. Overuse and misuse of antibiotics have contributed to the development of resistant strains, undermining the efficacy of standard treatments. This resistance not only complicates the management of infections but also poses significant public health challenges by prolonging recovery periods and increasing the risk of severe complications. As such, responsible antibiotic use is paramount to combat the spread of antibiotic-resistant chlamydia strains.

While chlamydia has traditionally responded well to standard antibiotics, such as azithromycin and doxycycline, reports of emerging resistance are on the rise. This resistance, particularly notable in azithromycin, underscores the need for vigilant monitoring and appropriate antibiotic stewardship. Healthcare providers play a critical role in this endeavour by adhering to updated treatment guidelines and prescribing antibiotics judiciously. Moreover, patient education on the importance of completing prescribed antibiotic courses as directed by healthcare professionals is essential in preventing the development of antibiotic resistance.⁶

Recent cases have shed light on the concerning trend of chlamydia infections persisting despite standard antibiotic treatment, demonstrating multidrug resistance. This poses a significant challenge in the clinical management of chlamydial infections and emphasizes the urgent need for improved treatment strategies. Enhanced surveillance of antibiotic resistance patterns and continued research into alternative treatment options is imperative to address this growing threat effectively. By understanding the dynamics of chlamydia infection and antibiotic resistance, healthcare providers can develop innovative approaches to mitigate the spread of resistant strains and safeguard public health.⁶

In conclusion, combating antibiotic resistance in chlamydia requires a multifaceted approach involving responsible antibiotic use, vigilant monitoring, and ongoing research. By implementing robust strategies for antibiotic stewardship and enhancing surveillance efforts, healthcare systems can better manage chlamydial infections and mitigate the impact of antibiotic resistance on public health. It is crucial for healthcare providers and policymakers to work collaboratively to address this pressing issue and ensure effective treatment outcomes for patients affected by chlamydia.

FAQ’s

Can chlamydia become resistant to antibiotics?

Yes, there have been reports of chlamydia strains developing resistance to antibiotics, particularly azithromycin. Antibiotic resistance can occur when bacteria mutate and adapt to the antibiotics used to treat them. Overuse or misuse of antibiotics can contribute to the development of resistant strains. While chlamydia has historically been susceptible to antibiotics, ongoing surveillance is essential to monitor resistance patterns and ensure effective treatment options remain available.

What should I do if my chlamydia infection doesn't respond to antibiotics?

If your chlamydia infection does not respond to the prescribed antibiotics, it's essential to consult your healthcare provider. They may recommend alternative antibiotics or a longer course of treatment based on the specific characteristics of your infection. In some cases, multidrug-resistant strains of chlamydia may require more aggressive treatment approaches. It's crucial to follow your healthcare provider's instructions closely and attend follow-up appointments to monitor your response to treatment.

How can I prevent antibiotic resistance in chlamydia?

To help prevent antibiotic resistance in chlamydia, it's essential to use antibiotics responsibly. This includes taking antibiotics exactly as prescribed by your healthcare provider, completing the full course of treatment, and avoiding sharing antibiotics or using leftover medication. Additionally, practising safer sex by using condoms can reduce the risk of chlamydia transmission and subsequent antibiotic use. Regular testing for sexually transmitted infections, including chlamydia, is also vital for early detection and treatment, which can help prevent the spread of antibiotic-resistant strains.

Summary

Chlamydia trachomatis is a prevalent sexually transmitted infection with significant public health implications, often remaining undetected due to its asymptomatic nature. The rise of antibiotic resistance complicates treatment efforts, underscoring the importance of effective management strategies. Through opportunistic screening, timely diagnosis, and appropriate antibiotic treatment, coupled with responsible antibiotic use and ongoing research into alternative treatments and resistance patterns, we can address this growing threat and improve global health outcomes.